MedTrace Logo

An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis

NCT05214794 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2026-02-13

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy of nemolizumab in systemic sclerosis patients. To evaluate also the safety and pharmacokinetics.

Conditions

Interventions

DRUG

nemolizumab

nemolizumab will be administered subcutaneous injection

Sponsors & Collaborators

  • Maruho Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Ayumi Yoshizaki, MD, PhD · Tokyo University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-20
Primary Completion
2024-06-04
Completion
2024-07-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05214794 on ClinicalTrials.gov